116 related articles for article (PubMed ID: 23802627)
1. Investigational cytokine-targeted therapies for ulcerative colitis.
Monteleone G; Pallone F; Caprioli F
Expert Opin Investig Drugs; 2013 Sep; 22(9):1123-32. PubMed ID: 23802627
[TBL] [Abstract][Full Text] [Related]
2. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.
Lawrance IC
Expert Opin Investig Drugs; 2015 Jun; 24(6):761-8. PubMed ID: 25719407
[TBL] [Abstract][Full Text] [Related]
3. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis.
Guimbaud R; Bertrand V; Chauvelot-Moachon L; Quartier G; Vidon N; Giroud JP; Couturier D; Chaussade S
Am J Gastroenterol; 1998 Dec; 93(12):2397-404. PubMed ID: 9860399
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive and biologic therapy for ulcerative colitis.
Ardizzone S; Cassinotti A; de Franchis R
Expert Opin Emerg Drugs; 2012 Dec; 17(4):449-67. PubMed ID: 23163556
[TBL] [Abstract][Full Text] [Related]
5. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids.
Nishimura R; Shirasaki T; Tsuchiya K; Miyake Y; Watanabe Y; Hibiya S; Watanabe S; Nakamura T; Watanabe M
J Gastroenterol; 2019 Jul; 54(7):608-620. PubMed ID: 30599053
[TBL] [Abstract][Full Text] [Related]
7. Emerging immunological targets in inflammatory bowel disease.
Monteleone G; Pallone F; MacDonald TT
Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
[TBL] [Abstract][Full Text] [Related]
8. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
9. Emerging oral drug options for ulcerative colitis.
Salvatori S; Neri B; Marafini I; Brigida M; Monteleone G
Expert Opin Emerg Drugs; 2023 Dec; 28(3):191-201. PubMed ID: 37668153
[TBL] [Abstract][Full Text] [Related]
10. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
11. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
12. The safety of non-biological treatments in Ulcerative Colitis.
Troncone E; Monteleone G
Expert Opin Drug Saf; 2017 Jul; 16(7):779-789. PubMed ID: 28608717
[TBL] [Abstract][Full Text] [Related]
13. Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.
Márquez L; Shen C; Cleynen I; De Hertogh G; Van Steen K; Machiels K; Perrier C; Ballet V; Organe S; Ferrante M; Henckaerts L; Galicia G; Rutgeerts P; Ceuppens JL; Vermeire S
Gut; 2012 Apr; 61(4):528-34. PubMed ID: 21708824
[TBL] [Abstract][Full Text] [Related]
14. New lessons: classic treatments, expanding options in ulcerative colitis.
Hanauer SB
Colorectal Dis; 2006 May; 8 Suppl 1():20-4. PubMed ID: 16594960
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Cohen RD; Woseth DM; Thisted RA; Hanauer SB
Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
[TBL] [Abstract][Full Text] [Related]
16. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development.
Caballol B; Gudiño V; Panes J; Salas A
Expert Opin Investig Drugs; 2021 Sep; 30(9):931-946. PubMed ID: 34365869
[TBL] [Abstract][Full Text] [Related]
17. Review article: Ulcerative colitis, smoking and nicotine therapy.
Lunney PC; Leong RW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):997-1008. PubMed ID: 23072629
[TBL] [Abstract][Full Text] [Related]
18. Oxazolone-induced murine model of ulcerative colitis.
Wang X; Ouyang Q; Luo WJ
Chin J Dig Dis; 2004; 5(4):165-8. PubMed ID: 15612886
[TBL] [Abstract][Full Text] [Related]
19. Th17-cytokine blockers as a new approach for treating inflammatory bowel disease.
Monteleone I; Pallone F; Monteleone G
Ann Med; 2011 May; 43(3):172-8. PubMed ID: 21114459
[TBL] [Abstract][Full Text] [Related]
20. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa.
Zwolinska-Wcislo M; Brzozowski T; Budak A; Kwiecien S; Sliwowski Z; Drozdowicz D; Trojanowska D; Rudnicka-Sosin L; Mach T; Konturek SJ; Pawlik WW
J Physiol Pharmacol; 2009 Mar; 60(1):107-18. PubMed ID: 19439813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
